The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects
Abstract
OBJECTIVE: As an adjunct to a reduced-calorie diet and increased physical activity, treatment with liraglutide 3.0 mg for weight management provides a statistically significant and clinically meaningful weight loss of 5.7%-8.0% compared to 1.6%-2.6% with placebo. The objective of this post hoc analysis was to quantify the relative contribution of weight loss to the treatment effects of liraglutide 3.0 mg on key efficacy endpoints. METHODS: The analysis utilized data from 4725 participants across three randomized, placebo-controlled, double-blind trials that evaluated the efficacy and safety of liraglutide 3.0 mg versus placebo, as an adjunct to a reduced-calorie diet and increased physical activity (ClinicalTrials.gov identifiers: NCT01272219, NCT01272232 and NCT01557166). The duration of two of the trials was 56 weeks; one trial was of 32 weeks' duration. A mediation analysis was performed, which ranked the relative contribution of weight loss to the treatment effects of liraglutide 3.0 mg on key cardiometabolic efficacy endpoints, Apnea-Hypopnea Index (AHI) and health-related quality of life (QoL). A limitation of this type of analysis is that it cannot conclusively prove a causal relationship. RESULTS: In individuals without type 2 diabetes mellitus (T2DM), endpoints predominantly driven by liraglutide-induced weight loss included waist circumference, diastolic blood pressure, triglycerides, high density lipoprotein cholesterol, AHI, and Impact of Weight on Quality of Life-Lite total and physical function scores. Endpoints predominantly independent of weight loss included the glycemic endpoints hemoglobin A1c and fasting plasma glucose in individuals with and without T2DM. Regardless of the degree of dependence on weight loss according to the mediation analysis, greater weight loss was associated with greater improvement in all endpoints. CONCLUSION: Treatment with liraglutide 3.0 mg contributes to improved cardiometabolic parameters, AHI and health-related QoL through both weight-loss dependent and weight-loss independent mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, hemoglobin A1c reduction can occur without weight change, and reduced risk of cardiovascular events appears to emerge before substantial weight reduction [38, 39].”
In the citing paper
“Although many of these benefits are weight‐dependent, others appear at least partly weight‐independent.”
In the citing paper
“For example, hemoglobin A1c reduction can occur without weight change, and reduced risk of cardiovascular events appears to emerge before substantial weight reduction [38, 39].”
In the citing paper
“Liraglutide improves many of the adiposopathic complications of obesity, such as high blood sugar, high blood pressure, and lipid parameters, via weight dependent and weight independent mechanisms [87].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [87]
In the citing paper
“Anti-obesity pharmacotherapies often have therapeutic properties that improve metabolic diseases beyond weight reduction alone (i.e., weight-dependent and weight-independent effects) [87].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [87]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citationDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Self-citationon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Self-citationvan Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Self-citationAdipocyte dysfunction, inflammation and metabolic syndrome
Klöting, N., & Blüher, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9301-0 · Cited by 472
Research works printed but not linked: 1
- American Society for Metabolic and Bariatric Surgery, Obesity Society, American Society of Bariatric Physicians, American Association of Clinical Endocrinologists. Joint press release: obesity is a disease: leading obesity groups agree. PRNewswire website. 2013. Available at: http://www.prnewswire.com/news-releases/obesity-is-a-disease-leading-obesity-groups-agree-212194851.html [Last accessed 15 December 2015]
Cited by
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Kolotkin, R. L., & Andersen, J. R. (2017) · Clinical Obesity · doi:10.1111/cob.12203 · Cited by 590
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Self-citationMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“For example, hemoglobin A1c reduction can occur without weight change, and reduced risk of cardiovascular events appears to emerge before substantial weight reduction [36, 37].”
Metadata
- Authors
- Bays, H., Pi-Sunyer, X., Hemmingsson, J. U., Claudius, B., Jensen, C. B., & Van Gaal, L.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Columbia University (US)
- Capio St Goran’s Hospital/Karolinska Institutet, Stockholm, Sweden;
- Novo Nordisk (Denmark) (DK)
- Department of Endocrinology, Diabetology and Metabolism, Faculty of Medicine, Antwerp University Hospital, Edegem, Belgium
- Corresponding author
- Bays, Harold
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2016-11-06
- Volume
- 33
- Issue
- 2
- Pages
- 225-229
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2547039088
- Cited by
- 48
- References
- 17
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 1 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 1
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- liraglutide, weight management, weight loss, obesity, type 2 diabetes, cardiometabolic outcomes, apnea-hypopnea index, sleep apnea, health-related quality of life, glycemic control, HbA1c, fasting blood glucose, waist circumference, triglycerides, diastolic blood pressure, GLP-1 receptor agonists, mediation analysis
- MeSH terms
- Liraglutide, Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Quality of Life, Weight Loss, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. https://app.cochat.ai/papers/10.1080/03007995.2016.1251892
- The paper
- Bays, H., Pi-Sunyer, X., Hemmingsson, J. U., Claudius, B., Jensen, C. B., & Van Gaal, L. (2017). Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2016.1251892
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.